Posts by VIVA! Communications
Simple blood test to detect early stage melanoma on horizon
Aussie researchers have developed the world’s first blood test to detect early stage melanoma. Researchers from Edith Cowan University (ECU), Perth produced the test after examining more than 1,600 functional proteins and identifying 10 auto-antibodies associated with melanoma. Early detection of melanoma is associated with an 80 – 95% survival rate. The blood test, which…
Read MoreDoctors sound alarm bell at lack of qualified nurses in aged care sector
Doctors have this week raised an alarm regarding the lack of qualified nurses working in the Australian aged care sector. According to the AMA’s most recent Aged Care survey, 35% of doctor respondents plan to stop accepting new patients, to reduce or completely cease their aged-care visits within the next two years. The survey involved…
Read MorePharmaxis granted FDA clearance to produce Aridol locally for US market
ASX-listed pharmaceutical company, Pharmaxis has today been granted FDA clearance to commence Sydney-based production of its asthma diagnostic medication, Aridol for the US. The approval follows hot-on-the-heels of the FDA’s recent inspection of the Sydney facility which manufactures Aridol for Australia, South Korea and Europe, and Bronchitol for Australia, Europe and Russia respectively. Following FDA…
Read MoreDoctors encouraging middle-aged Aussie blokes to consider their prostate
Doctors are encouraging middle-aged Aussie blokes to have their prostate checked.Their call coincides with an article published in MJA Insight today (Monday, August 13), citing benign prostatic hyperplasia (BPH) – or a benign enlargement of the prostate – can compromise a man’s quality of life, and his relationships with his partner and family.2 According…
Read MoreSeqirus to release additional 700,000 adult flu vaccine doses to help boost “community immunity” against preventable infection
Seqirus announced the manufacture of another 500,000 doses of their adult influenza vaccine, Afluria Quad (inactivated quadrivalent influenza vaccine, split virion) today to help meet increasing consumer demand. Having fulfilled the government’s request to re-enter production, Seqirus is now ahead of the National Immunisation Program (NIP) schedule, with its first vaccine set for release this…
Read More